For a patient with a thyroid nodule showing atypia on fine‑needle aspiration and a negative Afirma gene expression classifier (≈4% malignancy risk), when should the thyroid be re‑evaluated with ultrasound and repeat FNA?

Recommendation for Thyroid Re-evaluation After Negative Afirma Testing

For a thyroid nodule with atypia (Bethesda III) and a negative Afirma test (≈4% malignancy risk), repeat ultrasound surveillance should be performed at 1–2 years, with repeat FNA only if there are concerning ultrasound changes or significant size increase (≥20% in two dimensions).

Risk Stratification and Management Approach

The current 2022 French consensus guidelines 1 provide the most comprehensive framework for managing Bethesda III nodules. Your patient's negative Afirma result effectively reclassifies the nodule from the typical Bethesda III risk (10-30% malignancy) to a much lower risk category (≈4%), approaching that of a Bethesda II (benign) nodule.

Initial Surveillance Timeline

• First ultrasound follow-up: 1–2 years after the negative Afirma result 1
• Subsequent follow-up: Every 2–4 years if stable 1
• This conservative approach is supported by data showing that most nodules remain stable, and newly detected cancers are rare 1

Indications for Repeat FNA

Repeat FNA is warranted only if 1:

• Significant size increase: ≥20% increase in two of three dimensions (though context matters—a 20% increase in an 8mm nodule differs from a 4cm nodule)
• Ultrasound changes: Development of suspicious features (marked hypoechogenicity, microcalcifications, irregular margins, taller-than-wide orientation)
• EU-TIRADS score progression: Particularly if the nodule develops multiple high-risk features

The minimum interval for repeat FNA, if indicated, is 1–3 months 1, though research suggests 6 months or more is reasonable for nodules ≥10mm without progression 2.

Important Caveats and Clinical Nuances

Ultrasound Features Matter Most

The 2022 guidelines emphasize that ultrasound characteristics are critical for risk stratification 1:

• EU-TIRADS 5 nodules with multiple suspicious features (marked hypoechogenicity, higher-than-wide, microcalcifications, irregular margins) warrant closer surveillance even with negative molecular testing
• EU-TIRADS 3-4 nodules without suspicious features can be monitored less frequently

Size Considerations

• Nodules ≤2 cm: Active surveillance is a reasonable alternative even for Bethesda III without molecular testing 1
• Large nodules (>4cm): May warrant closer initial surveillance to establish growth trajectory 1

Molecular Testing Limitations

While the Afirma test has high negative predictive value (96-99% in various studies 3), it has low specificity (42-86%) 3. The negative result is most valuable for ruling out malignancy rather than confirming benignity. Research shows that:

• Afirma GSC has sensitivity of 94-96% but specificity of only 42-86% 3
• The 4% residual malignancy risk is comparable to Bethesda II (benign) nodules, which have 1-3% malignancy risk 1

Alternative Management Pathways

If repeat FNA becomes necessary and yields Bethesda III again 1:

• Surgery is usually recommended for nodules >2cm
• Active surveillance remains an option for nodules ≤2cm
• Consider core needle biopsy if repeat FNA is non-diagnostic

For nodules with ultrasound-cytology discordance (EU-TIRADS 5 with negative Afirma), maintain closer surveillance every 1–2 years for 5 years 1, as the malignancy risk may be 3-8.6% 1.

Practical Algorithm

1. Baseline: Document current nodule size and EU-TIRADS score
2. Year 1-2: First surveillance ultrasound
3. If stable: Repeat ultrasound every 2-4 years
4. If growth or suspicious changes: Repeat FNA
5. If decreased size: Continue surveillance (no nodules with decreased size were malignant in studies 2)

The 1-year repeat recommendation you mentioned is reasonable and aligns with current guidelines, though extending to 2 years is also acceptable for low-risk nodules 1, 4.